Message #12 From:
NewsBot Date: June 26, 2006 05:30:00 AM
IAGX News Imagenetix Appoints Former FDA, NIH Staffer to Guide IND Submission for Anti-Inflammatory Compound
SAN DIEGO--(BUSINESS WIRE)--June 26, 2006--Imagenetix, Inc. (OTCBB:IAGX) today announced it has engaged the services of Michael Hamrell, Ph.D., president of MORIAH Consultants, a regulatory affairs and clinical research consulting firm near Los Angeles.
Dr. Hamrell, who has held leading positions within the FDA and NIH and served as a regulatory affairs and pharmaceutical product development consultant for 25 years, will help guide Imagenetix' IND submission for its proprietary anti-inflammatory compound, 1-tetradecanol complex (1-TDC).
This guidance will include assisting Imagenetix' scientific staff in reviewing 1-TDC research to date, assessing additional studies necessary to meet FDA requirements to begin human clinical trials on the compound, preparing an IND application for 1-TDC, and submitting this application to the FDA.
1-TDC is intended for use as a pharmaceutical in the treatment of periodontal disease and other widespread inflammatory conditions.
The compound has recently achieved successful results in both animal acute toxicity and in-vitro efficacy studies.
"We are thrilled to align ourselves with Dr. Hamrell," said Imagenetix president William P. Spencer. "His breadth of knowledge and experience will be of great help in guiding Imagenetix through the IND submission process for 1-TDC, a compound we believe has great promise in the prescriptive marketplace."
San Diego-based Imagenetix, Inc., www.imagenetix.net, is developing novel drugs for the treatment of inflammatory diseases. The company also develops and markets natural-based, proprietary products, including over-the-counter topical creams and skin care products, for inflammation-related markets.
Safe Harbor Statement
This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company expects to file with the Securities Exchange Commission.
